EuroPCR 2026, the European Congress onInterventional Cardiology, was grandly held in Paris, France from May 19 to 22, 2026. During the session“Registries and trials in TMVR”, Professor WolfgangRottbauer from Ulm University Heart Center, Germany, presented the 3-year clinical outcomes of the HighLife3-Year Clinical Outcomes of HighLifeTSMVR Released with Significant LeftVentricular Reverse RemodelingEffectTSMVR technology, fully validating its efficacy and durability. Meanwhile, ProfessorLeonhard Schneider from the same center demonstrated the remarkableannularreduction effect and left ventricular reverse remodeling induced by HighLifeTSMVRvia a multicenter CT analysis. Professor Michael Joner fromtheGermanHeartCenter Munich shared 1-year follow-up data of the HighLife Clarityvalve, whichshowed no left ventricular outflow tract obstruction (LVOTO). Thesefindingsfurtherconfirm the clinical benefits brought by the sophisticated, innovativedesignofHighLife devices.
